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Abstract
The epidermal growth factor receptor (EGFR) inhibitor erlotinib has been shown to induce complete remission of
acute myeloid leukemia (AML) in two patients with concurrent lung cancer and raised attention for a role of EGFR
in AML whereas a recent phase II clinical study with gefitinib in AML demonstrated a negative result on the
outcome. However, from several studies, EGFR expression in AML is poorly defined and the role of EGFR in AML
remains unclear. Herein, we report the results of EGFR expression in AML of large cohorts of adult and pediatric
AML patients with the data of total protein and phosphorylation levels of EGFR. Our data conclude that there is the
expression of EGFR at the protein level in a subset of AML, which was identified to be functionally active in ~15 %
of AML patients. This suggests that future studies need to be conducted with a subset of AML patients
characterized by high EGFR expression.
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Epidermal growth factor receptor (EGFR) expression in
acute myeloid leukemia (AML) cells is a subject of con-
troversy, as there is no consensus about the expression
and activity of EGFR in AML. In non-small cell lung
cancer (NSCLC) patients, EGFR is known to be highly
expressed. The EGFR inhibitor erlotinib was shown to
induce complete remission of AML in two adult patients
with concurrent NSCLC and raised attention for EGFR
in AML [1, 2]. Especially NSCLC patients with rare
EGFR mutations had lower response rates to EGFR in-
hibitors than the patients with common mutations [3],
due to the counteraction of EGFR tyrosine kinase inhibi-
tors (TKIs) with specific EGFR mutations. In AML, pre-
vious reports showed that erlotinib was able to induce in
vitro differentiation, cell cycle arrest, and apoptosis of
AML blasts [4]. Another study showed that gefitinib, an-
other EGFR inhibitor, induced myeloid differentiation in
AML [5]. Additionally, EGFR expression was confirmed
by an experimental murine tumor of AML origin [6].
Gene expression of larger adult and pediatric AML
samples detected EGFR expression previously [7, 8]. In
contrast, EGFR protein levels, as assessed by immuno-
chemistry, and mRNA levels of EGFR have been found
to be doubtfully low in AML blasts [9, 10]. In AML cell
lines, EGFR is not expressed both at protein and mRNA
levels and the phenotypic effects of the EGFR inhibitors
must be due to off-target effects [9, 11]. Recently, Deangelo
et al. investigated the effect of EGFR inhibitor gefitinib in
adult AML patients (n = 18) in a phase II clinical study
[12]. Their results suggested that the single-agent gefitinib
has no effect on patient outcome due to undetectable
EGFR expression levels, both mRNA and protein. There-
fore, data on whether EGFR is expressed, the actual level of
expression, and if EGFR is present in an activated post-
translationally modified phosphorylated state in AML has
not been consistent in previous studies using small subsets
of AML patients. Herein, we demonstrate the EGFR ex-
pression in total protein and protein phosphorylation levels
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We investigated total EGFR protein expression as well as
EGFR phosphorylation in AML blasts using reverse phase
protein array (RPPA) in a large cohort of adult AML pa-
tients (n = 511) and EGFR peptide phosphorylation levels
using peptide phosphorylation array of AML patients both
pediatric and adult (n = 96 + 83 = 179). The details of the
sample collections and the methods of RPPA and peptide
phosphorylation array are described [13, 14] in the design
and methods section (Additional file 1: Design and
methods). In this report, we demonstrate that the EGFR
protein (n = 511) is expressed and active in a subset of
AML patients. Expression of both total and Y992 phos-
phorylated EGFR protein was readily detected both in nor-
mal bone marrow (NBM)-derived CD34+ cells and in
AML blasts, with expression following a Gaussian distribu-
tion. In the primary AML samples, expression of total
EGFR protein was higher than that of NBM CD34+ cells
in 11 % and expression of phosphorylated EGFR exceeded
NBM in 18 % of cases (Fig. 1a, b). Interestingly, the total
EGFR expression and EGFR phosphorylation data are cor-
related significantly (p < 0.0001). There was no significant
difference of molecular and clinical characteristics (e.g.,
age, sex, WHO classification, FAB classification, karyo-
types, blast percentage, white blood cell count, hemoglobin
concentration, platelet count, complete response rate, re-
lapse frequencies, death frequencies, FLT3-ITD, FLT3-
D835, and NPM1 mutations) found between the 11 %
AML (high EGFR) patients and the rest of the 89 % AML
(low EGFR) patients (Additional file 2: Table S1). In
addition, EGFR tyrosine kinase is functionally active in
AML blasts, as demonstrated by peptide phosphorylation
activity of EGFR-related peptides using peptide phosphor-
ylation profiling arrays in a large cohort of AML patients
(n = 179) (Fig. 1c). These results indicate that EGFR protein
is both expressed and present in activated phosphorylated
forms in AML, supporting EGFR as a potential therapeutic
target in EGFR-expressing AML patients. The RPPA data-
set is available at http://bioinformatics.mdanderson.org/
supplements.html (under “RPPA Data in AML”) and the
processed raw data of peptides phosphorylation can be
found in the additional information (Additional file 3: Pep-
tide phosphorylation data for Fig. 1c).
The discordance between the readily detectable EGFR
protein levels observed in this study and the lack of EGFR
expression seen in some other analyses, as well as the lack
of clinical efficacy of EGFR inhibitors seen in prior clinical
trials, can be explained with our data. Patients included in
previous studies could belong to the group of 85 % of
AML samples which showed the same levels of EGFR ex-
pression as normal CD34+ cells in our study. The inclu-
sion of only patients with low expression might account
for the lack of response to gefitinib in AML patients (n =
18) evaluated in the phase II study by Deangelo et al. [12].
Altogether, our data shows increased expression of
EGFR at both the total protein (11 %) and protein phos-
phorylation (18 %) levels in a subset of AML patients
compared to normal CD34+ samples. Results of future
clinical studies of EGFR inhibitors might be improved if
they are restricted to patients with highly expressed
EGFR or active phosphorylated EGFR. Notably, muta-
tions of EGFR were not observed in the TCGA analyses
of AML, so consideration of mutation status is not re-
quired in AML as it is for lung cancer [15].
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Fig. 1 The total EGFR protein expression, phosphorylation of EGFR and EGFR peptides phosphorylation in primary AML samples. a Total EGFR
protein expression was measured using RPPA of 511 adult AML samples. Total EGFR protein was highly expressed in 11 % (57/511) of the adult
AML samples versus the CD34+ normal bone marrow (NBM) samples. The distribution density of total EGFR expression was depicted in the
figure. b Similarly, the EGFR protein phosphorylation levels were measured using RPPA of the same 511 adult AML samples. EGFR protein
phosphorylation levels were 18 % (93/511) higher in adult AML patient samples compared to the CD34+ NBM samples. c The EGFR peptide
phosphorylations were measured using PepChipTM Kinomics microarray system of 179 AML patients. The median of four EGFR peptides with
different phosphorylation sites was used to make the graph
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